Get the Stockscreener App
2.82
2.08%
-0.06
After Hours:
2.83
0.01
+0.35%
Incannex Healthcare Inc stock is traded at $2.82, with a volume of 28,539.
It is down -2.08% in the last 24 hours and down -25.79% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$2.88
Open:
$2.88
24h Volume:
28,539
Relative Volume:
0.46
Market Cap:
$35.38M
Revenue:
$12,000
Net Income/Loss:
$-48.41M
P/E Ratio:
-0.1641
EPS:
-17.181
Net Cash Flow:
$-19.99M
1W Performance:
-9.03%
1M Performance:
-25.79%
6M Performance:
-21.88%
1Y Performance:
-73.14%
1-Day Range:
$2.815
$2.9389
1-Week Range:
$2.75
$3.10
52-Week Range:
$2.49
$14.91
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
2.82 | 35.38M | 12,000 | -48.41M | -19.99M | -17.18 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc Stock (IXHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-26 | Initiated | Alliance Global Partners | Buy |
Incannex Healthcare Inc Stock (IXHL) Latest News
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - The Manila Times
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Why Did Incannex (NASDAQ:IXHL) Dose Its First Sleep-Apnea Patient? - Kalkine Media
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com South Africa
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com Nigeria
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Begins Dosing in Phase 2 Sleep Apnea Trial - minichart.com.sg
Incannex begins Phase 2 dosing study for sleep apnea drug - Investing.com
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com Canada
A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan
IXHLIncannex Healthcare Inc Revenue Breakdown - Finviz
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Enterprise value to EBIT forward of Incannex Healthcare Limited – LSX:A2DF4D - TradingView
IXHL Q4'26 Earnings: EPS estimate is (0.14) USD - TradingView
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29ETF Premium Discount - vinanet.vn
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29Change of Character - dars.gov.et
What’s Next for Incannex Healthcare (ASX:IHL) After US Patent Win? - Kalkine Media
IXHL Q4'26 Earnings: revenue estimate is 0 USD - TradingView
Incannex doses first patient in sleep apnea drug trial By Investing.com - Investing.com Nigeria
Incannex doses first patient in sleep apnea drug trial - Investing.com India
Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus
Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - Quiver Quantitative
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Barchart.com
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - The Manila Times
Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - Kalkine Media
Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media
Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusTrend Continuation Trade - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneGap and Reverse - dars.gov.et
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusVolatility Skew - dars.gov.et
Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media
Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media
Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media
Incannex Healthcare Inc. (IXHL) options chain - Yahoo Finance Singapore
Incannex Secures A$5.1M R&D Tax Incentive Refund - theglobeandmail.com
Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight? - Kalkine Media
Why Are BrainChip (ASX:BRN), Incannex Healthcare (ASX:IHL), Lake Resources (ASX:LKE) and Cann Group (ASX:CAN) Back in the Market Spotlight? - Kalkine Media
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com UK
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com Australia
Incannex receives final A$5.1m R&D tax incentive refund - Investing.com
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - The Manila Times
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Australia
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Canada
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - marketscreener.com
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.14%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):